Cargando…
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors
INTRODUCTION: Surgical procedures in persons with haemophilia A or B with inhibitors (PwHABI) require the use of bypassing agents (BPA) and carry a high risk of complications. Historically, only two BPAs have been available; these are reported to have variable responses. AIM: To prospectively evalua...
Autores principales: | Escobar, Miguel, Luck, James, Averianov, Yevhenii, Ducore, Jonathan, Fernández, Maria Fernanda López, Giermasz, Adam, Hart, Daniel P., Journeycake, Janna, Kessler, Craig, Leissinger, Cindy, Mahlangu, Johnny, Martinez, Laura Villarreal, Miesbach, Wolfgang, Mitha, Ismail Haroon, Quon, Doris, Reding, Mark T., Schved, Jean‐François, Stasyshyn, Oleksandra, Vilchevska, Kateryna V., Wang, Michael, Windyga, Jerzy, Alexander, W. Allan, Al‐Sabbagh, Ahmad, Bonzo, Daniel, Mitchell, Ian S., Wilkinson, Thomas A., Hermans, Cédric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292306/ https://www.ncbi.nlm.nih.gov/pubmed/34614267 http://dx.doi.org/10.1111/hae.14418 |
Ejemplares similares
-
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors
por: Escobar, Miguel, et al.
Publicado: (2021) -
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors
por: Pipe, Steven W., et al.
Publicado: (2022) -
Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma
por: Grandoni, Jerry, et al.
Publicado: (2021) -
Eptacog-α/prednisone/rituximab: No response: case report
Publicado: (2021) -
Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study
por: Windyga, Jerzy, et al.
Publicado: (2020)